Reversal-specific learning impairments after a binge regimen of methamphetamine in rats: possible involvement of striatal dopamine.
A growing body of evidence indicates that protracted use of methamphetamine (mAMPH) causes long-term impairments in cognitive function in humans. Aside from the widely reported problems with attention, mAMPH users exhibit learning and memory deficits, particularly on tasks requiring response control. Although binge mAMPH administration to animals results in cognitive deficits, few studies have attempted to test behavioral flexibility in animals after mAMPH exposure. The aim of this study was to evaluate whether mAMPH would produce impairments in two tasks assessing flexible responding in rats: a touchscreen-based discrimination-reversal learning task and an attentional set shift task (ASST) based on a hallmark test of executive function in humans, the Wisconsin Card Sort. We treated male Long-Evans rats with a regimen of four injections of 2 mg/kg mAMPH (or vehicle) within a single day, a dosing regimen shown earlier to produce object recognition impairments. We then tested them on (1) reversal learning after pretreatment discrimination learning or (2) the ASST. Early reversal learning accuracy was impaired in mAMPH-treated rats. MAMPH pretreatment also selectively impaired reversal performance during ASST testing, leaving set-shifting performance intact. Postmortem analysis of [(125)I]RTI-55 binding revealed small (10-20%) but significant reductions in striatal dopamine transporters produced by this mAMPH regimen. Together, these results lend new information to the growing field documenting impaired cognition after mAMPH exposure, and constitute a rat model of the widely reported decision-making deficits resulting from mAMPH abuse seen in humans.
Department of Psychology, California State University, Los Angeles, CA 90032, USA. aizquie@calstatela.edu
Alicia
A
Izquierdo
Annabelle M
AM
Belcher
Lori
L
Scott
Victor A
VA
Cazares
Jack
J
Chen
Steven J
SJ
O'Dell
Melissa
M
Malvaez
Tiffany
T
Wu
John F
JF
Marshall
D000704:Analysis of Variance; D000818:Animals; D001288:Attention / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D003042:Cocaine / Q000031:analogs & derivatives / Q000378:metabolism; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D004192:Discrimination, Psychological / Q000187:drug effects; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D007859:Learning Disabilities / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects*; D009483:Neuropsychological Tests; D010775:Photic Stimulation / Q000379:methods; D011485:Protein Binding / Q000187:drug effects; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000378:metabolism; D051381:Rats; D020318:Rats, Long-Evans; D021641:Recognition, Psychology / Q000187:drug effects; D012193:Reversal Learning / Q000187:drug effects*
D000697:Central Nervous System Stimulants; D050483:Dopamine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals; D008694:Methamphetamine; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; D003042:Cocaine; D004298:Dopamine